Wall Street brokerages expect Sangamo Therapeutics Inc (NASDAQ:SGMO) to announce earnings of ($0.10) per share for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for Sangamo Therapeutics’ earnings. The highest EPS estimate is $0.07 and the lowest is ($0.24). Sangamo Therapeutics posted earnings per share of ($0.15) during the same quarter last year, which would suggest a positive year-over-year growth rate of 33.3%. The firm is expected to issue its next earnings report on Thursday, November 8th.
On average, analysts expect that Sangamo Therapeutics will report full year earnings of ($0.60) per share for the current fiscal year, with EPS estimates ranging from ($0.89) to ($0.29). For the next financial year, analysts anticipate that the firm will report earnings of ($0.78) per share, with EPS estimates ranging from ($1.06) to ($0.29). Zacks Investment Research’s EPS calculations are a mean average based on a survey of research analysts that follow Sangamo Therapeutics.
Sangamo Therapeutics (NASDAQ:SGMO) last released its quarterly earnings results on Wednesday, August 8th. The biopharmaceutical company reported ($0.17) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.15) by ($0.02). The firm had revenue of $21.42 million during the quarter, compared to analyst estimates of $21.43 million. Sangamo Therapeutics had a negative net margin of 105.65% and a negative return on equity of 26.36%. Sangamo Therapeutics’s quarterly revenue was up 159.6% on a year-over-year basis. During the same quarter last year, the firm earned ($0.17) earnings per share.
In other Sangamo Therapeutics news, CFO Kathy Yi sold 5,000 shares of the company’s stock in a transaction that occurred on Tuesday, May 15th. The shares were sold at an average price of $15.38, for a total value of $76,900.00. Following the completion of the sale, the chief financial officer now owns 12,250 shares of the company’s stock, valued at $188,405. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last three months, insiders have sold 30,000 shares of company stock valued at $458,700. 1.20% of the stock is currently owned by insiders.
A number of large investors have recently modified their holdings of the business. NumerixS Investment Technologies Inc bought a new stake in Sangamo Therapeutics in the second quarter valued at approximately $125,000. Riverhead Capital Management LLC increased its stake in Sangamo Therapeutics by 218.0% in the second quarter. Riverhead Capital Management LLC now owns 8,267 shares of the biopharmaceutical company’s stock valued at $117,000 after purchasing an additional 5,667 shares in the last quarter. Tyers Asset Management LLC increased its stake in Sangamo Therapeutics by 301.3% in the second quarter. Tyers Asset Management LLC now owns 9,632 shares of the biopharmaceutical company’s stock valued at $137,000 after purchasing an additional 7,232 shares in the last quarter. Meadow Creek Investment Management LLC increased its stake in Sangamo Therapeutics by 301.3% in the second quarter. Meadow Creek Investment Management LLC now owns 16,856 shares of the biopharmaceutical company’s stock valued at $239,000 after purchasing an additional 12,656 shares in the last quarter. Finally, Tiverton Asset Management LLC bought a new stake in Sangamo Therapeutics in the second quarter valued at approximately $242,000. 57.49% of the stock is owned by hedge funds and other institutional investors.
Sangamo Therapeutics traded up $0.35, reaching $15.65, on Friday, MarketBeat.com reports. The stock had a trading volume of 2,113,880 shares, compared to its average volume of 1,967,697. Sangamo Therapeutics has a 1-year low of $9.50 and a 1-year high of $27.50. The company has a debt-to-equity ratio of 0.07, a quick ratio of 4.78 and a current ratio of 7.24.
About Sangamo Therapeutics
Sangamo Therapeutics, Inc focuses on translating ground-breaking science into genomic therapies that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company's zinc finger DNA-binding protein (ZFP) technology enables specific genome editing and gene regulation.
See Also: What is a Leveraged Buyout (LBO)?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.